Apogee Therapeutics Inc (APGE) Stock Price, Quote & News

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and e...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

StockMarketToday247 Sep. 2 at 3:03 PM

$GOSS $CAMP $TRAW $APGE #Biotech #CapitalMarkets Clinical and regulatory catalysts are increasingly being written directly into financing structures. Recent deals tie later capital tranches to FDA acceptance, trial clearance, enrollment or clinical data. That creates a second layer of catalyst risk: success can raise asset value AND unlock runway. Failure can hit valuation AND remove expected capital. The screen I care about now: funded cash committed milestone capital optional warrant proceeds extra trigger conditions “Up to $100M” is not the same thing as $100M of liquidity. The better catalyst question: what happens to the balance sheet the morning after the result? That’s where we've got our eyes today. https://stockmarkettoday.beehiiv.com/p/biotech-catalysts-are-becoming-financing-events

1 · Reply

Mergerbrief Sep. 2 at 12:11 PM

$APGE / $ABBV expected to close today. No second request, no litigation, no activist, no drama. Announced, tendered, done. Not every deal needs a story. Some of them just pay you.

0 · Reply

STRelativeStrength Aug. 31 at 2:05 PM

$APGE undiscovered breakout with 459 watchers

0 · Reply

STRelativeStrength Aug. 26 at 5:36 PM

$APGE undiscovered breakout with 460 watchers

0 · Reply

TwongStocks Aug. 26 at 5:21 PM

$APGE Equity Corporate Actions Alert #2026 - 607 Information Regarding the Merger of Apogee Therapeutics, Inc. (APGE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-607 At a special meeting held on August 11, 2026, the shareholders of Apogee Therapeutics, Inc. (APGE), approved the proposed merger with and into AbbVie Inc. (NYSE: $ABBV ). The merger is tentatively scheduled to close prior to the market open on September 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 2, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (September 3rd) and will be suspended effective September 4, 2026. APGE shareholders will receive $135.11 per share at closing.

0 · Reply

Mandalo Aug. 21 at 7:35 AM

$APGE $LLY $NVO The story is one of the more interesting ones that I’ve ever seen in the drug delivery space. "Rani Therapeutics at Canaccord Genuity conference: oral biologics push" https://www.investing.com/news/transcripts/rani-therapeutics-at-canaccord-genuity-conference-oral-biologics-push-93CH-4855907

0 · Reply

Mandalo Aug. 20 at 10:16 AM

$APGE & $RANI are two of the most exciting plays in drug delivery and therapeutics. While Apogee is pushing the boundaries with ultra-long-acting biologics to cut down injection frequency to just a few times a year, Rani Therapeutics is pioneering the holy grail: converting injectable biologics into simple oral capsules with the RaniPill. Both companies address massive chronic disease markets—like immunology and metabolic health—where patient compliance is everything. Apogee extends the dosing window, and Rani eliminates the needle altogether. Exceptional leadership, game-changing technology platforms, and massive commercial potential make both of these biotech innovators major multi-bagger candidates for long-term investors! 🚀📈 #Biotech #Stocks #Investing 😇🤑👍

2 · Reply

miller1m Aug. 17 at 2:43 AM

$APGE any idea when this deal closes? It says sometime in Q3. Hoping before end of August.

1 · Reply

Mergerbrief Aug. 11 at 12:12 PM

$APGE / $ABBV – Shareholder Vote APGE

0 · Reply

Pika_Capital Aug. 10 at 3:27 PM

$ORKA $SYRE they will most likely be gone too for a nice premium after $APGE riding it through

1 · Reply

AbbVie completes acquisition of Apogee for $135.11 per share in cash

ABBV

Sep 3, 2026, 8:34 AM EDT - 9 hours ago

AbbVie Completes Acquisition of Apogee Therapeutics

ABBV

2026-08-17T10:16:35.000Z - 17 days ago

Apogee Therapeutics downgraded to Neutral from Buy at BTIG

2026-08-17T07:46:22.000Z - 17 days ago

Apogee Therapeutics price target raised to $135 from $81 at Truist

ABBV

Aug 10, 2026, 7:00 AM EDT - 24 days ago

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Aug 10, 2026, 7:00 AM EDT - 24 days ago

Apogee Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 24 days ago

Apogee Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 4 weeks ago

Apogee Therapeutics Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 4 weeks ago

Apogee Therapeutics Proxy statement: Proxy filing

Jul 13, 2026, 5:06 PM EDT - 7 weeks ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

ABBV SBIO

Jul 13, 2026, 8:00 AM EDT - 7 weeks ago

Apogee Therapeutics Proxy statement: Proxy filing

Jul 2, 2026, 8:00 AM EDT - 2 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI JNJ LLY MRNA SNY XBI

Jun 26, 2026, 8:00 AM EDT - 2 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

ABBV

2026-06-24T13:35:15.000Z - 2 months ago

Apogee Therapeutics downgraded to Hold from Buy at Stifel

2026-06-24T09:00:21.000Z - 2 months ago

Apogee Therapeutics downgraded to Neutral from Outperform at Mizuho

2026-06-23T21:45:11.000Z - 2 months ago

Apogee Therapeutics downgraded to Hold from Buy at TD Cowen

ABBV

2026-06-23T12:26:54.000Z - 2 months ago

Apogee Therapeutics downgraded to Neutral from Buy at Guggenheim

2026-06-23T12:22:00.000Z - 2 months ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

ABBV

2026-06-23T11:29:50.000Z - 2 months ago

Apogee Therapeutics moved to No Rating at BofA

ABBV

2026-06-23T11:28:00.000Z - 2 months ago

Apogee Therapeutics downgraded to Neutral from Buy at Citi

2026-06-23T09:26:30.000Z - 2 months ago

Apogee Therapeutics downgraded to Neutral from Buy at UBS

2026-06-22T21:55:09.000Z - 2 months ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

ABBV EVMN

2026-06-22T19:45:24.000Z - 2 months ago

Apogee Therapeutics downgraded to Hold from Buy at Deutsche Bank

2026-06-22T16:11:00.000Z - 2 months ago

Apogee Therapeutics rises 46.8%

2026-06-22T15:55:21.000Z - 2 months ago

Apogee Therapeutics downgraded to Hold from Buy at Craig-Hallum

2026-06-22T15:00:08.000Z - 2 months ago

Apogee Therapeutics downgraded to Neutral from Outperform at Wedbush

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

ABBV CRDO MU

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

ABBV

2026-06-22T14:11:39.000Z - 2 months ago

Apogee Therapeutics rises 46.7%

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

ABBV

Jun 22, 2026, 7:06 AM EDT - 2 months ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

ABBV

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

ABBV

Jun 22, 2026, 7:00 AM EDT - 2 months ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

ABBV

Jun 22, 2026, 5:56 AM EDT - 2 months ago

Intel, Micron, SpaceX, Apogee Therapeutics, and More Stocks That Explain Today's Market

INTC MU SPCX

Jun 20, 2026, 12:11 PM EDT - 2 months ago

AbbVie would gain an experimental eczema drug by buying biotech: report

ABBV

Jun 19, 2026, 11:17 AM EDT - 2 months ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

ABBV

Jun 10, 2026, 9:20 AM EDT - 2 months ago

Apogee Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:00 AM EDT - 2 months ago

Apogee Therapeutics Transcript: AGM 2026

Jun 3, 2026, 11:40 AM EDT - 3 months ago

Apogee Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:01 PM EDT - 3 months ago

Apogee Therapeutics to Participate in Upcoming June Conferences

May 27, 2026, 8:49 AM EDT - 3 months ago

Apogee secures up to $1.3 billion from Blackstone to advance eczema drug

May 27, 2026, 8:00 AM EDT - 3 months ago

Apogee Therapeutics Transcript: Study result

May 27, 2026, 8:00 AM EDT - 3 months ago

Apogee Therapeutics Slides: Study result

May 27, 2026, 8:00 AM EDT - 3 months ago

Apogee Therapeutics Press release: Study result

May 27, 2026, 6:31 AM EDT - 3 months ago

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

May 27, 2026, 6:30 AM EDT - 3 months ago

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

May 26, 2026, 4:01 PM EDT - 3 months ago

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

May 11, 2026, 7:00 AM EDT - 3 months ago

Apogee Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Apogee Therapeutics Quarterly report: Q1 2026

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Mar 26, 2026, 4:01 PM EDT - 5 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Mar 24, 2026, 9:53 PM EDT - 5 months ago

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Mar 23, 2026, 4:01 PM EDT - 5 months ago

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Apogee Therapeutics Transcript: Study result

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Apogee Therapeutics Press release: Study result

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Apogee Therapeutics Slides: Study result

Mar 23, 2026, 6:30 AM EDT - 5 months ago

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

Mar 22, 2026, 7:51 PM EDT - 5 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Mar 3, 2026, 9:10 AM EST - 6 months ago

Apogee Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 6 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Mar 2, 2026, 7:00 AM EST - 6 months ago

Apogee Therapeutics Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 6 months ago

Apogee Therapeutics Annual report: Q4 2025

Mar 2, 2026, 7:00 AM EST - 6 months ago

Apogee Therapeutics Slides: Corporate presentation

Feb 24, 2026, 7:30 AM EST - 6 months ago

Apogee Therapeutics to Participate in Upcoming March Conferences

Feb 12, 2026, 2:00 PM EST - 6 months ago

Apogee Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 7 months ago

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 6, 2026, 8:00 AM EST - 8 months ago

Apogee Therapeutics Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Apogee Therapeutics Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 8 months ago

Apogee Therapeutics Slides: Study Result

Jan 6, 2026, 6:00 AM EST - 8 months ago

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Jan 5, 2026, 4:01 PM EST - 8 months ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Dec 3, 2025, 9:45 AM EST - 9 months ago

Apogee Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Nov 19, 2025, 10:00 AM EST - 9 months ago

Apogee Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 12:30 PM EST - 9 months ago

Apogee Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 11:20 AM EST - 9 months ago

Apogee Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 1:30 PM EST - 9 months ago

Apogee Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 7:10 AM EST - 9 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 7:00 AM EST - 9 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Nov 10, 2025, 7:00 AM EST - 9 months ago

Apogee Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Apogee Therapeutics Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 9 months ago

Apogee Therapeutics Slides: Corporate Presentation

Nov 3, 2025, 7:30 AM EST - 10 months ago

Apogee Therapeutics to Participate in Upcoming Conferences

Oct 10, 2025, 4:01 PM EDT - 10 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Oct 8, 2025, 9:52 PM EDT - 10 months ago

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Oct 8, 2025, 4:01 PM EDT - 11 months ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Sep 16, 2025, 11:30 AM EDT - 11 months ago

Apogee Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 11, 2025, 7:30 AM EDT - 11 months ago

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Sep 3, 2025, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Earnings release: Q2 2025

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Transcript: Study Result

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Press release: Study Result

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Study Result

Jul 7, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Corporate Presentation

Jul 7, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Jul 6, 2025, 6:00 PM EDT - 1 year ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Jun 5, 2025, 10:30 AM EDT - 1 year ago

Apogee Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 13, 2025, 4:40 PM EDT - 1 year ago

Apogee Therapeutics Transcript: Bank of America 2025 Healthcare Conference

May 12, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Investor Presentation

May 12, 2025, 6:05 AM EDT - 1 year ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

May 12, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

May 12, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Quarterly report: Q1 2025

May 12, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Earnings release: Q1 2025

May 9, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Corporate Presentation

May 1, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 8:40 AM EDT - 1 year ago

Apogee Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 4, 2025, 2:30 PM EST - 1 year ago

Apogee Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:30 AM EST - 1 year ago

Apogee Therapeutics Transcript: Study Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Apogee Therapeutics Press release: Study Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Apogee Therapeutics Slides: Study Update

Mar 3, 2025, 7:00 AM EST - 1 year ago

Apogee Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

Apogee Therapeutics Annual report: Q4 2024

Mar 3, 2025, 6:05 AM EST - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

StockMarketToday247 Sep. 2 at 3:03 PM

1 · Reply

Mergerbrief Sep. 2 at 12:11 PM

$APGE / $ABBV expected to close today. No second request, no litigation, no activist, no drama. Announced, tendered, done. Not every deal needs a story. Some of them just pay you.

0 · Reply

STRelativeStrength Aug. 31 at 2:05 PM

$APGE undiscovered breakout with 459 watchers

0 · Reply

STRelativeStrength Aug. 26 at 5:36 PM

$APGE undiscovered breakout with 460 watchers

0 · Reply

TwongStocks Aug. 26 at 5:21 PM

0 · Reply

Mandalo Aug. 21 at 7:35 AM

0 · Reply

Mandalo Aug. 20 at 10:16 AM

2 · Reply

miller1m Aug. 17 at 2:43 AM

$APGE any idea when this deal closes? It says sometime in Q3. Hoping before end of August.

1 · Reply

Mergerbrief Aug. 11 at 12:12 PM

$APGE / $ABBV – Shareholder Vote APGE

0 · Reply

Pika_Capital Aug. 10 at 3:27 PM

$ORKA $SYRE they will most likely be gone too for a nice premium after $APGE riding it through

1 · Reply

topstockalerts Aug. 5 at 12:52 AM

AbbVie launched a $10 billion investment-grade bond offering to help finance its pending $10.9 billion acquisition of Apogee Therapeutics, with demand reaching approximately $63 billion, according to sources familiar with the deal. The offering, originally expected to raise at least $8 billion, includes nine tranches with maturities ranging from 2 to 40 years, while pricing tightened significantly as investor demand exceeded expectations. The proceeds will fund the acquisition, announced in June and expected to close this quarter, strengthening AbbVie's immunology portfolio as competition intensifies for its blockbuster drug Skyrizi. The financing follows stronger-than-expected second-quarter results, supported by robust demand in the company's immunology and neuroscience businesses and improving trends in its Botox franchise. The transaction is one of the largest U.S. investment-grade bond sales of 2026 outside the AI-driven financing boom. $ABBV $APGE

0 · Reply

NezuRIP Jul. 25 at 8:26 AM

$APGE 11 aug

0 · Reply

miller1m Jul. 24 at 1:03 PM

$APGE currently higher than the buyout [email protected]

0 · Reply

BostonDave Jul. 24 at 10:07 AM

$ALT $APGE $FOLD $TECH $TERN

0 · Reply

BuddyBoy6975 Jul. 24 at 1:29 AM

$ALT $APGE $FOLD $TECH $TERN So, in your Tern chart, short interest increased over a 6 month period by 1.5-2.5 times its SI 6 months earlier. Wow. Then hit Not fairy tale gobbledygook. Legitimate. Market. Analysis. 👏👏👏👏👏👏👏👏👏👏

0 · Reply

TradeSun Jul. 23 at 5:49 PM

$ALT $APGE $FOLD $TECH Short interest of $TERN kept growing and were running into Merck s BO- Offer on March 25 😉👇

1 · Reply

BuddyBoy6975 Jul. 23 at 1:57 AM

$ALT $APGE $FOLD $TECH Trade, interesting thoughts on WHY we see rising short interest and an increase in Bashers ahead of BO news…

0 · Reply

TradeSun Jul. 22 at 10:01 PM

$ALT $APGE $FOLD $TECH What I can tell you without any more dd, Dilution is not uncommon before a deal. Basta!

1 · Reply

HansWurst19 Jul. 22 at 7:48 PM

$ALT $TECH $APGE $FOLD interesting. Have you matched it with the available shares of those companies? Maybe it's just that they diluted too and mire available shares meant more shorting? Or dilution means upcoming buyout?

1 · Reply

BuddyBoy6975 Jul. 22 at 7:33 PM

$ALT $APGE $FOLD $TECH Trade, that’s a HELLUVA find. Great job man….🙏🙏😎😎

1 · Reply

TradeSun Jul. 22 at 7:14 PM

$ALT $APGE $FOLD $TECH For FSDdingsbums… 👇 @Hatrak1

0 · Reply

Pika_Capital Jul. 17 at 5:43 PM

$ORKA $APGE $SYRE Holy moly what a run. In less than a year orka and syre jumped +500%, and apge was bought out. +250% And honestly if it was not about my man Oneil Trader (Growth Stock Forum sub on Seeking Alpha) I probably would not have gotten into these names. Give it a try if you want to grow as biotech investor. SA is full of shit as a platform but he does not want to pivot elsewhere for now. I brought in few guys and noone really complained. If you are reading this and did sub because of my recommendation, comment below and share feedback

0 · Reply

Market Cap	8.40B
Revenue (ttm)	0.00
Net Income (ttm)	-255.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,142,000
Avg Vol	1,808,356
Day's Range	N/A - N/A
Shares Out	62.20M
Stochastic %K	95%
Beta	0.33
Analysts	Sell
Price Target	$134.53